Insmed, Inc.

INSMNASDAQ • USD
121.16 USD
↗ 3.09 (2.62%)AT CLOSE (03:59 PM EST)
120.39
↘ 0.77 (0.63%)
POST MARKET (AS OF 04:14 PM EST)
Post Market
AS OF 04:14 PM EST
120.39
↘ 0.77 (0.63%)
🔴Market: CLOSED

INSM is currently priced at $121.16. Technicals currently rate "Buy" while our fundamental analysis reads "Neutral". Key drivers include a robust Altman Z-Score, negative Return on Equity and a bearish Death Cross on the long-term moving averages. Furthermore, INSM is currently richly valued, trading at a premium to sector peers across key valuation metrics.

Technical & fundamental data as of Nov 13, 2026.

Open?$118.18
High?$121.54
Low?$116.97
Prev. Close?$118.07
Volume?1.5M
Avg. Volume?3.6M
VWAP?$119.64
Rel. Volume?0.43x
Bid / Ask
Bid?$118.90 × 100
Ask?$121.88 × 100
Spread?$2.98
Midpoint?$120.39
Valuation & Ratios
Market Cap?26.6B
Shares Out?219.4M
Float?214.3M
Float %?98.1%
P/E Ratio?N/A
P/B Ratio?36.60
EPS?-$2.76
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
Employees
1.7K
Market Cap
26.6B
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2000-06-01
Address
700 US HIGHWAY 202/206
BRIDGEWATER, NJ 08807
Phone: 908-977-9900
Technical OutlookBuy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+1/3)
Medium-Term (Wave)?▲ Bullish(+2/3)
Short-Term (Ripple)?– Neutral(0/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
23
Z-Score?
100
Momentum?
98
Short Sent.?
69
Piotroski F-Score?3/9Weak
Altman Z-Score?7.36Safe
Confidence?60%Moderate
Full Fundamental Analysis →
Short InterestElevated
Short % of Float?6.57%Elevated
Short Interest?14.1M
Days to Cover?3.6
Free Float214.3M
Avg Daily Volume4.0M
Settlement Date2026-10-30
Financial Health
Current Ratio?2.86Strong
Quick Ratio?2.59Strong
Cash Ratio?0.66Adequate
Debt/Equity?0.79Moderate
ValuationRICHLY VALUEDvs 1 peers + S&P 500
Score
50/100
P/E?
N/A▾
P/B?
Peers
100
S&P
3
36.60HIGH▾
P/S?
Peers
100
S&P
3
17.49HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-49.6CHEAP▾
EV/Sales?
Peers
100
S&P
3
17.61HIGH▾
Returns & Efficiency
ROE?
S&P
3
-83.4%WEAK▾
ROA?
S&P
3
-27.2%WEAK▾
Cash Flow & Enterprise
FCF?$-627575000
Enterprise Value?$26.8B
Fundamentals ratios updated end of day